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Introduction: Patients with ankylosing spondylitis require a team approach from multiple
professionals, various treatment modalities for continuous periods of time, and can lead to
the  loss of labour capacity in a young population. So, it is necessary to measure its socio-
economic impact.
Objectives: To describe the use of public resources to treat AS in a tertiary hospital after
the  use of biological medications was approved for treating spondyloarthritis in the Health
Public System, establishing approximate values for the direct and indirect costs of treating
this  illness in Brazil.
Material and methods: 93 patients selected from the ambulatory spondyloarthritis clinic at
the  Hospital de Clínicas of the Federal University of Paraná between September 2011 and
September 2012 had their direct costs indirect treatment costs estimation.
Results: 70 patients (75.28%) were male and 23 (24.72%) female. The mean age was 43.95
years. The disease duration was calculated based on the age of diagnosis and the mean was
8.92  years (standard deviation: 7.32); 63.44% were using anti-tumour necrotic factor drugs.
Comparing male and female patients the mean Bath Ankylosing Spondylitis Disease Activity
Index was 4.64 and 5.49 while the mean Bath Ankylosing Spondylitis Functional Index was
5.03  and 6.35 respectively.
Conclusions: The Brazilian public health system’s spending related to ankylosing spondylitis
has  increased in recent years. An important part of these costs is due to the introduction
of  new, more  expensive health technologies, as in the case of nuclear magnetic resonance
and, mainly, the incorporation of anti-tumour necrotic factor therapy into the therapeutic
arsenal. The mean annual direct and indirect cost to the Brazilian public health system totreat  a patient with ankylosing spondylitis, according to our ﬁndings, is US$ 23,183.56.©  2015 Elsevier Editora Ltda. All rights reserved.
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Custos  diretos  e  indiretos  do  tratamento  de  pacientes  com  espondilite
anquilosante  pelo  sistema  público  de  saúde  brasileiro
Palavras-chave:
Espondilite anquilosante
Custos indiretos
Farmacoeconomia
Qualidade de vida
Custos diretos
r  e  s  u  m  o
Introduc¸ão: Os pacientes com espondilite anquilosante (EA) exigem uma abordagem de
equipe com vários proﬁssionais e várias modalidades de tratamento, continuamente; além
disso, a doenc¸a pode levar à perda da capacidade de trabalho em uma populac¸ão jovem, de
modo que é necessário medir o seu impacto socioeconômico.
Objetivos: Descrever o uso de recursos públicos para o tratamento da EA em um hospi-
tal terciário após o uso dos fármacos biológicos ter sido aprovado para o tratamento das
espondiloartrites pelo Sistema Público de Saúde e estabelecer valores aproximados para os
custos diretos e indiretos do tratamento dessa doenc¸a no Brasil.
Material e métodos: Foram estimados os custos de tratamento diretos e indiretos de 93
pacientes com EA do ambulatório de espondiloartrite do Hospital de Clínicas da Univer-
sidade Federal do Paraná, entre setembro de 2011 e setembro 2012.
Resultados: Dos pacientes, 70 (75,28%) eram do sexo masculino e 23 (24,72%) do feminino.
A  idade média foi de 43,95 anos. A durac¸ão da doenc¸a foi calculada com base na idade
do  diagnóstico e a média foi de 8,92 anos (desvio padrão: 7,32); 63,44% dos indivíduos
usavam fármacos anti-TNF. Na comparac¸ão dos pacientes dos sexos masculino e feminino,
a  média no Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) foi de 4,64 e 5,49,
enquanto a média no Bath Ankylosing Spondylitis Functional Index (BASFI) foi de 5,03 e
6,35,  respectivamente.
Conclusões: Os gastos do sistema público de saúde brasileiro relacionados com a espondilite
anquilosante aumentaram nos últimos anos. Uma parte importante desses custos deve-se à
introduc¸ão  das novas tecnologias de saúde, mais dispendiosas, como no caso da ressonân-
cia  nuclear magnética e, principalmente, da incorporac¸ão da terapia anti-TNF ao arsenal
terapêutico. O custo médio anual direto e indireto do sistema público de saúde brasileiro
para tratar de um paciente com espondilite anquilosante, de acordo com os resultados deste
estudo, é de US$ 23.183,56.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Ankylosing Spondylitis (AS) is a chronic inﬂammatory dis-
ease, autoimmune in origin, which generally affects the spinal
column and can evolve into stiffness and progressive func-
tional limitation of the axial skeleton.1,2 It is more  frequent
in young adults aged between 20 and 40 years. There is a
greater prevalence in males (3:1), Caucasians, and HLA-B27
positive individuals.2,3 The HLA-B27 antigen is strongly corre-
lated with the appearance of the disease, and a positive test
for this marker is found in 80–98% of cases.4 It is a progressive
disease which, over time, causes the patient’s quality of life to
deteriorate. In advanced stages, it may lead to complete spinal
ankyloses, known as “bamboo spine”, and extreme reduction
of mobility. Even in the initial stage of the disease, inﬂam-
matory lumbar pain may cause signiﬁcant morbidity in the
patient, complicating daily activities and even requiring tem-
porary leave from work duties. Many  patients suffer from the
progressive loss of their capacity to work, which may result
in early retirement, generating additional costs to the public
welfare system.5,6The introduction of anti-TNF (anti-tumour necrotic factor)
pharmaceuticals to treat AS in 2006 guaranteed patients bet-
ter quality of life thanks to the efﬁcacy of these medicationsin lessening symptoms and the progression of the disease.
Despite the efﬁcacy and safety these medications provide,
their high costs greatly impact health budgets in countries
where these drugs were implemented. Various studies of cost
effectiveness have been conducted in an attempt to assess
differences between the anti-TNF therapies.7–9
Because this incapacitating disease requires a team
approach from multiple professionals, various treatment
modalities for continuous periods of time, and can lead to the
loss of labour capacity in a young population, it is necessary
to measure its socio-economic impact. International studies
of the direct and indirect annual costs of AS have indicated a
value of approximately 10 thousand euros per patient.10,11
The last Brazilian study intended to demonstrate the direct
and indirect costs in AS patients was published in 2010, and
demonstrated signiﬁcant differences between the domestic
and international situations. The domestic cost was estimated
at U$4597 per patient/year. This value was low in compari-
son with the ﬁndings of international studies that had been
published up to that point.12 However, the Brazilian study
was  conducted before anti-TNF-alpha medications had been
fully introduced into the Brazilian public health system (the
Sistema Único de Saúde, or SUS). During the study period,
anti-TNF medications were utilised by 13% of AS patients,
representing 80% of medication costs.12
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Table 1 – Clinical and demographic data of ankylosing spondylitis patients treated at HC-UFPR Spondyloarthritis
outpatient clinic.
Data Men (70) Women (23) Total
Age (years) mean (SD) 44.55 (10.61) 41.52 (10.70) 43.80 (10.66)
Mean disease time in years (SD) 9.76 (7.22) 6.39 (7.32) 8.92 (7.36)
Ankylosis (%) 45 (64.28) 14 (60.86) 59 (63.44)
Sacroiliitis (%) 63 (90) 19 (82.60) 82 (88.17)
HLA-B27+ (%) 48 (68.57) 19 (82.60) 67 (72)
Mean BASDAI (SD) 4.64 (2.52) 5.49 (2.41) 4.86 (2.49)
Mean BASFI (SD) 5.03  (2.86) 6.35 (2.66) 5.36 (2.84)
Use of anti-TNF˛  drugs (%) 45  (64.28) 14 (60.86) 59  (63.44)
Mean ASQoL (SD) 12  (5.58) 13 (3.95) 10.57 (5.25)
Education (%)
<9 years 25.7 43.4 30.1
9–12 years 42.8 26 38.7
>12 years 31.4  30.4 31.1
Individual income (%)
<1 Salary 23.8 59 31.8
1–3 Salaries 58 31.8 51.6
3–5 Salaries 14.4 9 13
>5 Salaries 4.3 0 3
ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index; TNF, tumour necrotic factor.
eviat
l
o
l
d
M
W
s
U
b
s
y
2
t
i
w
q
t
t
(
A
(
t
s
H
i
e
t
i
sData with normal distribution were expressed in mean and standard d
The minimum wage used as reference is U$ 306.40.
The objective of this study was to describe the use of pub-
ic resources to treat AS in a tertiary hospital after the use
f biological medications was approved for treating spondy-
oarthritis in the SUS, establishing approximate values for the
irect and indirect costs of treating this illness in Brazil.
aterials  and  methods
e  describe a transversal study of a sample of 93 patients
elected from the outpatient spondyloarthritis clinic at the
niversidade Federal do Paraná (UFPR) – Hospital de Clínicas
etween September 2011 and September 2012. The inclu-
ion criteria were being diagnosed with AS for at least a
ear according to modiﬁed New York criteria, fulﬁl the ASAS
009 classiﬁcation for axial spondyloarthritis and being older
han 18 years old. Patients who  present malignancies, acute
nfections and other rheumatologic and autoimmune diseases
ere excluded from the study.
Before an outpatient clinic visit each patient answered a
uestionnaire about its demographical and economical sta-
us, clinical story, pensions and welfares received, considering
he previous twelve months. Disease indexes such as BASFI
Bath Ankylosing Spondylitis Functional Index), BASDAI (Bath
nkylosing Spondylitis Disease Activity Index), and ASQoL
Ankylosing Spondylitis Quality of Life) were also assessed at
his moment.
The direct costs are deﬁned as the sum of all resources
pent to directly treat and manage AS patients.13 The National
ealth System provides most of the care without any payment
ncluding medical care, medications, laboratory and radiologic
xams and physical therapy. Equipment and home adapta-
ions were also classiﬁed in direct costs regard its importance
n the management of the disease despite being a private
pend. Indirect Costs are all the resources spent by theion. Non normal data were expressed in median and 25–75 percentile.
Brazilian government with welfares, disease pensions and
retirement due incapacity resulted from AS.
We performed a descriptive analysis of the direct costs
obtained according to the Brazilian health system cost table
which applied to the period of 2012.14 The cost ﬁndings were
converted from brazilian real into dollar using the exchange
rate from the last day of September 2012 (U$ 1 = R$ 2,03), when
the study period ended.
The indirect costs estimation took in consideration sick
leaves and retirements resulted from the disease. The total
amount was calculated based on the national minimum wage
for that period, which was U$ 306.40.15
The patients were informed about the objective of the study
and signed the Free and Informed Consent Agreement. The
study was approved by the Ethics Committee of the Universi-
dade Federal do Paraná – Hospital de Clínicas.
Results
Of the 93 patients with ankylosing spondylitis 70 (75.28%) were
male and 23 (24.72%) female. The mean age was 43.95 years,
and included individuals between 21 and 69 years of age. The
duration of the disease was calculated based on the age of
diagnosis, and the mean was 8.92 years (standard deviation:
7.32); 63.44% were using anti-TNF drugs. Comparing male and
female patients the mean BASDAI was 4.64 and 5.49 while
the mean BASFI was 5.03 and 6.35 respectively; 83.4% of the
sample received less than three salaries as individual income.
Other demographic and clinical data are exposed in Table 1.The data related to the costs of complementary exami-
nations are summarised in Table 2, and the data pertaining
to spending on medications is outlined in Table 3. The
total cost with medication is U$ 1.926,429,24, with anti-TNF
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Table 2 – Complementary examinations conducted in the last 12 months on patients with AS who were  monitored by the
HC-UFPR spondyloarthritis outpatient clinic.
Complementary examinations N◦ of exams conducted Unit cost Total cost Cost per patient
Hemogram 372 3.36 1253.43 13.477
ESR (sedimentation rate) 372 1.34 500.27 5.37
CRP (C-reactive protein) 372 4.55 1695.07 18.22
Bilirubins 197 0.99 195.05 2.09
Liver transaminases 197 1.98 390.11 4.19
Tuberculin (PPD) 27 0 0 0
anti-HBs 27 9.13 246.72 2.65
HbsAg (Hepatitis B Surface Antigen) 27 9.13 246.72 2.65
anti-HCV 27 9.13 246.72 2.65
X-rays 165 4.92 812.80 8.73
Computer Tomography 24 49.80 1195.27 12.85
Magnetic resonance image of sacroiliac joint 16 132.38 2118.22 22.77
Shoulder ultrasound 4 11.92 47.68 0.51
HLA-B27 test 34 – – –
Echocardiogram 1 19.67 19.67 0.21
Analysis of synovial ﬂuid 1 1.82 1.82 0.01
Total 1863 8969.62 96.44
. ValuAverage price calculated from the most commonly requested images
representing 97.96% (1.887,131,43), NSAIDs 0.58% (11.249,84)
and DMARDs 1.09% (21.131,2) of this amount.
The direct costs are reported in Table 4 and indirect costs
in Table 5.
The total cost for the sample was U$ 2,156,070.83/year, rep-
resenting U$ 23,183.56 per patient/year.
Discussion
In Brazil, there is a scarcity of studies that evaluate the impact
of the costs of treating patients with ankylosing spondylitis.
Furthermore, although this was not our objective, we noted
that studies of cost effectiveness related to AS are almost non-
existent compared to the proportion of studies in European
countries and the United States. This is the ﬁrst study con-
ducted in Brazil that assesses the costs of AS after the full
Table 3 – All drugs prescribed for treatment of
ankylosing spondylitis during an one year period.
Medication Number of
patients using
the drug
Total cost of
medication/year
Adalimumab 28 884,947.41
Inﬂiximab 17 423,234.71
Etanercept 14 578,949.31
Methotrexate 13 974.64
Leﬂunomide 2 1226.50
Sulfasalazine 30 18,930.06
NSAIDs 70 11,249.84
Prednisone 13 1013.60
Other drugs 30 5903.17
Total 1,926,429.24
Values are shown in dollar. Other drugs include Omeprazole, Folic
Acid, Codeine, Cyclobenzaprine and Amitriptyline.es are shown in dollar.
introduction of biological medications by the SUS for treat-
ment of this afﬂiction.
The study sample was mainly composed of men  and the
mean age was 44 years. The mean disease duration was
approximately 9 years, differing from the results found by
Torres, which was 16 years.12
The mean BASFI functional score was 5.36, and the BASDAI
was 4.86, similar values to those found by Torres (BASFI = 5
and BASDAI = 4), suggesting a similar sample with relation to
functional state and disease activity. As for quality of life, the
mean ASQoL score was 10.57, also higher than the ﬁndings by
Torres (ASQoL = 8); nevertheless, as this index has not yet been
validated in a Brazilian Portuguese version, comparisons may
be controversial.
The total number of complementary examinations
requested for the group was 1863. The most commonly
requested tests were laboratory evaluations, principally
hemograms, ESR, CRP, liver enzyme panels and bilirubins,
used to assess disease activity and to monitor the side effects
of immunosuppressant therapy. The costs spent on imaging
accounted for 46.8% of total examination costs, compared
with the 56% obtained by Torres. Although this author did not
conduct more  expensive tests such as computer tomography
(CT) and nuclear magnetic resonance (NMR), that study
described greater utilisation of examinations such as X-rays
and bone density scans.12
Only 16 NMRs were ordered, despite the growing impor-
tance of this test to the early diagnosis of the disease,
principally for diagnosing axial spondyloarthritis according to
ASAS classiﬁcation when no alterations are evident in con-
ventional radiography imaging of the spinal column or the
sacroiliac joint.16 However, the patients selected had had their
diagnosis well established for at least one year prior to the
study. As both of the facilities where the studies were con-
ducted are very similar (tertiary public university hospitals),
we can observe that the utilisation of this test has grown,
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Table 4 – Total direct costs related to treatment of ankylosing spondylitis patients during an one year period.
Total cost Percent of direct costs Total cost per patient
Direct costs
Anti-TNF  1,887,131.43 96.21 20,291.74
Other drugs 39,297.80 2.00 422.56
Medical consultations 1832.51 0.09 19.70
Physical therapy 2424.71 0.12 26.07
Complementary examinations 8969.63 0.46 96.45
Adaptations 20,714.28 1.06 222.73
Equipment 1133.99 0.06 12.19
Total 1,961,504.34 100.00 21,091.44
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ontributing to the increase in the direct costs of diagnosing
nd treating the disease.
Non-steroidal anti-inﬂammatories were the most widely
sed medications in this study; however, the cost of these
edications corresponds to approximately 0.6% of the total
pending on medications. The second most widely used class
f medications was the biologicals, corresponding 63.44% of
he sample. The cost of these drugs corresponded to 97.96%
f the spending on medications and 87.53% of the total cost
f treatment. The larger proportion of spending on biological
edications had already been observed in Brazil; in that sam-
le, only 13.33% of the sample used biological medications but
hese were responsible for 80% of drug spending and 74% of
he total cost.12 Our objective was not to compare the costs of
ifferent biological therapies, as this is the subject of a study
urrently underway at the same facility.
Physical therapy was responsible for a small increase in
osts, US$ 26.00 per person, which demonstrates a small
egree to which this therapeutic resource is used.
Only 14 patients reported costs related to adapting their
esidences, representing only 1% of direct costs of the disease.
evertheless, this number may not correspond to reality, as it
epends on the subjects’ memories. Costs related to trans-
ortation were not obtained due to the degree of difﬁculty
ssociated with the sample subjects providing this informa-
ion in retrospect; however, Torres reported in his study that
hese costs could represent around 2% of direct costs and 1%
f total costs.12
Indirect costs associated with retirement and sick leave
onstitute 8.9% of total costs. As the disease primarily affects
oung people in the productive age ranges, inability to work
s one of the factors that contributes to the increase in total
osts. Nearly 59% of the sample was retired or on leave from
ork as a result of the disease, which is similar to the ﬁndings
y Torres (56%).
Table 5 – Total indirect costs related to treatment of ankylosing
human capital approach.
Number of patients (% of total num
Retirement due to AS 51 (54.83%) 
Sick leave due to AS 4 (4.30%) 
Unemployed 8 (8.6%)a
a 21.05% of the non-retired patients who were not on sick leave. Values arIn the current study, total annual costs to treat 93 patients
with AS reached a total of US$ 2,156,070.83 dollars/year and
a mean value of US$ 23,183.56/patient/year, while Torres’s
study found a total of 4597.00/patient/year. An increase in the
cost of treating AS patients in Brazil over the last three years
was found, particularly as a result of the addition of anti-TNF
agents to the therapeutic arsenal in treating spondyloarthri-
tis.
The direct costs were US$ 1,961,504.34, corresponding to
90.9% of total costs, while indirect costs were US$ 194,566.49,
corresponding to only 9.1% of total costs. This data indicates
a divergence from the data generated by Torres’s study, which
found direct costs of 45% and indirect costs of 55%, despite
the fact that the total number of retired patients and patients
on leave were similar in both studies. The result we  obtained
was principally due to the higher costs of treatment with
anti-TNF agents, which are now used on a larger scale in
Brazil.
The introduction of new medications based on the rec-
ommendations of the ASAS group and the Brazilian Society
of Rheumatology since 2006 have revolutionised the treat-
ment of people with axial spondyloarthritis.16–19 Patients
with AS are prescribed anti-TNF medications after the fail-
ure of at least two non-steroidal anti-inﬂammatories (NSAIDs)
over a period of three months, without the need to use
disease-modifying antirheumatic drugs (DMARDs) before-
hand, according to the Brazilian public health system (SUS)
protocol.20 Consequently, there is an earlier use of these bio-
pharmaceuticals in AS compared with other diseases such
as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) with
peripheral manifestations, for example, in which it is neces-
sary to demonstrate the therapeutic failure of at least two
DMARDs.
In Brazil, three anti-TNF medications are available for treat-
ing AS patients in the public health system. In our sample,
 spondylitis patients during an one year period based on
ber) Total cost Cost per patient
184,761.57  3622.78
9804.92 2451.23
e shown in dollar.
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none of the patients had the ﬁnancial resources to pay for
their treatment themselves, considering the mean individual
and household income of each, as well as the fact that they
also did not have access to private health plans. Furthermore,
during the period this data was being collected, it was rare to
ﬁnd cases of AS patients being treated by the private health
care system.
Due to the increase in the incoherent costs of treatment
with anti-TNF agents, cost effectiveness studies have been
conducted. Studies by Kobelt et al.8,9 indicate that inﬂiximab
is cost-effective and its use is justiﬁed by the increase in qual-
ity of life and the reduction of the costs of the disease; at the
same time, Boonen et al.10 propose the need to identify the
patients in which treatment with inﬂiximab and etanercept
will be effective and cost-effective because of the high costs
associated with treatment with biologicals. At this present
time, there have been no studies of cost-effectiveness in Brazil.
Brazil has few studies about the socio-economic and ﬁnan-
cial impact of rheumatologic diseases. Due to the large
expanse of the country and especially inequalities in acces-
sing diagnostic procedures and therapies, the cost projections
should not be generalised.
We  also believe that, with regard to the increase in direct
costs associated with AS, the overall scene encountered in
South America should not differ from the ﬁndings in Brazil, as
the majority of countries on the continent have incorporated
anti-TNF therapy into the treatment of AS patients.
It is important to stress that studies of the impact on quality
of life have reinforced the need for more  effective participation
by other health professionals in the monitoring and treatment
of patients with AS, and this also could be responsible for a
partial increase in costs.21,22
An additional limitation of our study is that although the
authors believe that the clinical and epidemiological charac-
teristics of the patient sample are representative of the other
patients served by the SUS, our study tracked a sample served
at a university hospital located in a large state capital in Brazil,
a city where access to more  expensive health technologies
such as nuclear magnetic resonance imaging has been eas-
ier in relation to the challenges faced by patients in other SUS
hospitals in more  remote locations throughout Brazil.
Conclusions
The Brazilian public health system’s spending related to anky-
losing spondylitis has increased in recent years. An important
part of these costs is due to the introduction of new, more
expensive health technologies, as in the case of nuclear mag-
netic resonance and, principally, the costs resulting from the
incorporation of anti-TNF biological therapy into the thera-
peutic arsenal. The mean annual direct and indirect cost to
the Brazilian public health system to treat a patient with anky-
losing spondylitis, according to our ﬁndings, is US$ 23,183.56.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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